CAR-T cells can be effective protein delivery vehicles to treat lymphoma

GSK gene therapy

Researchers at Memorial Sloan Kettering have discovered something new about CAR-T immunotherapy: The cells can act as delivery vehicles for proteins that have the potential to treat lymphoma.

In patients with follicular lymphoma, a receptor called HVEM is mutated half of the time, and the mutations can lead to growth of the cancer. To combat this, the scientists engineered a CAR-T cell to deliver the HVEM protein normally produced by healthy cells. And the CAR-T cell acts as a sort of “micro-pharmacy” that continuously makes the protein locally.

In animal tests, the protein-producing CAR-T cells performed better than the control.

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

Previously, CAR-T cells were thought to directly attack cancer cells, but the new research, published in Cell, demonstrates they can have even more of an impact.

Suggested Articles

A Mount Sinai-led team found that immune cells in the brain protect it from abnormal activation that can lead to behavioral problems.

Sanford Burnham Prebys researchers showed that blocking the formation of the nuclear pore complex in cancer cells can slow their growth.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.